Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: crysball who wrote (1483)	10/30/1998 8:18:00 AM
From: yosi s	Respond to of 1491

I thought that HU 211 is in phase 3 I will have to check again. Tamoxiphen analogue is at least 5 Q away,and as such it is not that relevent. Though The indication is nice, and news media exposure is very nice, But the news is old old old.

To: crysball who wrote (1483)	10/30/1998 9:00:00 AM
From: wolfdog2	Respond to of 1491

crysball, slow down. The potential market is huge. But at the current time no one knows how PARS tamoxifen drug will fare. More over, PARS is not the only company with a tamoxifen analogue. Ligand has one as well. I suspect other companies do too.

To: crysball who wrote (1483)	10/30/1998 12:46:00 PM
From: Omer Shvili	Respond to of 1491

crysball, You're absolutely right, management should be applauded for choosing the right direction once again. PARS' Tamoxifen project isn't a high risk project, as they try to improve an already approved drug (as opposed to discovering some novel compound, just according to their strategy like we all know). PARS will seek a partner for Tamoxifen methiodide (or some other analog they find attractive) sooner than with HU211. They won't try to push the project all the way to PIII, they'll get a partner much sooner. In that sense, '99 could be very interesting, as we could sign a partner for Tamoxifen as well as HU211 - now that is some exposure !!! PARS will try to do some sort of a PI/PII trial in '99, just to show some trends of efficacy and safety. This is supposed to attract a partner, who will push the project through larger scale clinical trials and, hopefully, all the way to FDA approval. In any event, PARS and Ruder Finn can use this huge interest in breast cancer in general, and specifically in Tamoxifen to their advantage. Having a drug in the pipeline that exactly fits this huge need from the market, especially as the papers keep reporting about this need, is a great benefit to any company, not alone a small biotech like PARS. PARS will become profitable next year, according to all the articles posted here, that makes them part of a small group ~30 companies out of ~300 public biotech companies. That alone makes them attractive and should help them pop on many radar screens next year. On top of this they have a very exciting pipeline with HU211 and Tamoxifen, and remember HU211 is not one drug (it's a family of compounds that can produce 2-5 different drugs, 3 of which blockbusters, i.e. TBI, stroke and MS). All this for under $2 per share (market cap less than $75), which makes PARS one of the biggest bargains out there.